Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC combined with sintilimab and sorafenib for advanced hepatocellular carcinoma
ChiCTR2000031437Phase 2Not yet recruiting
- Sponsor
- Department of Interventional Therapy, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and sorafenib in hepatocellular carcinoma (HCC), sponsored by Department of Interventional Therapy, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
sintilimabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000031437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031437.